[Federal Register Volume 62, Number 195 (Wednesday, October 8, 1997)]
[Notices]
[Pages 52568-52569]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-26630]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health is seeking licensees for the 
further development, evaluation, and commercialization of novel 
progesterone antagonists and pharmaceutical compositions thereof. The 
invention claimed in U.S. Patent Application 60/016,628 entitled ``21-
Substituted Progesterone Derivatives As New Antiprogestational Agents'' 
(HK Kim, RP Blye, PN Rao, JW Cessac, and CK Acosta), filed May 1, 1996, 
and a related case filed April 30, 1997, are available for either 
exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 
and 37 CFR Part 404).

ADDRESSES: Licensing proposals and questions about this opportunity 
should be addressed to Ms. Carol Lavrich,

[[Page 52569]]

Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301/496-7735 ext. 287; fax: 
301/402-0220; e-mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0f4c433d3e5d4f4146472148405921">[email protected]</a>
    Information about the patent applications and pertinent information 
not yet publicly described can be obtained under a Confidential 
Disclosure Agreement. Respondees interested in licensing the 
invention(s) will be required to submit an Application for License to 
Public Health Service Inventions.

SUPPLEMENTARY INFORMATION: As part of its continuing steroid synthesis 
program and its expanded mission, the Contraception and Reproductive 
Health Branch, Center for Population, National Institute of Child 
Health and Human Development, has developed several 21-substituted 
derivatives of progesterone for therapeutic applications as 
antiprogestational agents.
    Preclinical evaluation of these steroids indicates greater 
antiprogestational activity and reduced antiglucocorticoid activity 
compared with mifepristone. These data and those derived from a number 
of endocrinological, reproductive and receptor binding studies are 
available for the process of due diligence. None of these data has been 
published. Radioimmunoassays for these steroids are being developed. No 
toxicological studies have been undertaken, but extensive safety 
studies have been performed on a similar antiprogestational agent.
    Antiprogestational agents have a broad spectrum of potential 
therapeutic uses in gynecic medicine including cervical ripening, 
endometriosis, uterine fibroids, breast and endometrial cancer and 
postmenopausal hormone replacement therapy.
    Applicants for licensing are encouraged to submit a research plan 
which encompasses the most extensive development for therapeutic use.

    Dated: September 26, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-26630 Filed 10-7-97; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>